Q1 Earnings Estimate for LRMR Issued By HC Wainwright

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Larimar Therapeutics in a research note issued on Tuesday, March 25th. HC Wainwright analyst E. White expects that the company will post earnings of ($0.43) per share for the quarter. HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Larimar Therapeutics’ Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.54) EPS and FY2027 earnings at ($1.57) EPS.

Other research analysts also recently issued reports about the stock. Guggenheim reaffirmed a “buy” rating and issued a $26.00 target price on shares of Larimar Therapeutics in a research report on Tuesday. Robert W. Baird dropped their price objective on Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating on the stock in a report on Tuesday. Finally, Truist Financial initiated coverage on Larimar Therapeutics in a report on Wednesday, January 29th. They issued a “buy” rating and a $18.00 target price for the company. Eleven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $20.22.

Larimar Therapeutics Trading Down 2.6 %

LRMR stock opened at $2.25 on Wednesday. The stock has a market cap of $143.57 million, a P/E ratio of -1.96 and a beta of 0.99. Larimar Therapeutics has a twelve month low of $2.19 and a twelve month high of $11.20. The company’s 50 day moving average is $3.11 and its two-hundred day moving average is $5.18.

Larimar Therapeutics (NASDAQ:LRMR) last posted its earnings results on Monday, March 24th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.16).

Hedge Funds Weigh In On Larimar Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Quest Partners LLC raised its stake in Larimar Therapeutics by 171.1% during the 3rd quarter. Quest Partners LLC now owns 9,183 shares of the company’s stock valued at $60,000 after acquiring an additional 5,796 shares during the last quarter. Intech Investment Management LLC acquired a new position in shares of Larimar Therapeutics in the third quarter valued at approximately $85,000. Janus Henderson Group PLC raised its stake in shares of Larimar Therapeutics by 27.2% during the third quarter. Janus Henderson Group PLC now owns 5,566,855 shares of the company’s stock worth $36,379,000 after purchasing an additional 1,189,467 shares during the last quarter. Quarry LP lifted its holdings in shares of Larimar Therapeutics by 50.0% during the third quarter. Quarry LP now owns 12,000 shares of the company’s stock worth $79,000 after purchasing an additional 4,000 shares during the period. Finally, Sphera Funds Management LTD. lifted its holdings in shares of Larimar Therapeutics by 32.6% during the third quarter. Sphera Funds Management LTD. now owns 414,478 shares of the company’s stock worth $2,715,000 after purchasing an additional 102,009 shares during the period. Hedge funds and other institutional investors own 91.92% of the company’s stock.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.